Global Chorea Treatment Market

Chorea Treatment Comprehensive Study by Type (Chorea-Acanthocytosis Treatment, Sydenham’s Chorea Treatment), Application (Hospitals, Clinics, Therapy Center, Others), Treatment (Medication, - Fluphenazine {Prolixin}, - Haloperidol {Haldo}, - Olanzapine {Zyprexa}, - Quetiapine {Seroque}, - Risperidone {Risperdal}, Surgery, Home Care), Diagnosis (Blood Tests, Brain Imaging {Magnetic Resonance Imaging or Computed Tomography}, Others), End User (Adults, Children, Adolescents) Players and Region - Global Market Outlook to 2028

Chorea Treatment Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Chorea disease is the movement disorder causing sudden, involuntary and unpredictable body movements. Chorea is the primary feature of Huntington’s disease which is the progressive, hereditary movement disorder that appears commonly in adults but can also happen to children due to the genetic condition. The symptoms of chorea can range from minor movements such as fidgeting, uncontrolled arm or leg movements which can be interfered with posture, swallowing and speech problem. The disorder causes neurological abnormalities and affects the functioning of the brain. There are two types of chorea ie. Chorea-Acanthocytosis, Sydenham’s Chorea. However, there is actually no such standard treatment for chorea, as it depends on the type of chorea and other associated with a disease where Huntington's disease can be treated while Sydenham's chorea generally involves the antibiotics for the infection.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledTeva Pharmaceutical Industries Ltd. (Israel), Medtronic plc (Ireland), Boston Scientific Corporation (United States), Bausch Health Companies Inc. (Canada), Camber Pharmaceuticals Inc (United States), LivaNova, PLC (United Kingdom), H. Lundbeck A/S (Denmark), Ipsen (France), Amgen Inc. (United States) and Aleva Neurotherapeutics SA (Switzerland)


This growth is primarily driven by Rising Prevalence of Genetic Conditions, such as Huntington’s Disease and Increasing Various Neurological Problems like Immune Condition and Metabolic Disorder.

Globally, a noticeable market trend is evident Continuous Research and Development in Chorea Treatment Major Players, such as Teva Pharmaceutical Industries Ltd. (Israel), Medtronic plc (Ireland), Boston Scientific Corporation (United States), Bausch Health Companies Inc. (Canada), Camber Pharmaceuticals Inc (United States), LivaNova, PLC (United Kingdom), H. Lundbeck A/S (Denmark), Ipsen (France), Amgen Inc. (United States) and Aleva Neurotherapeutics SA (Switzerland), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The competitive landscape of the cholera treatment market includes information by competitor. Company overview, financials, revenue generated, market potential, investment in R&D, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, and technology lifeline curve are all included. The data points presented above are only linked to the companies' concentration on the chorea treatment sector.

In 2019, Teva Pharmaceutical Industries Ltd. announced the Phase 2/3 ARTISTS 1 and Phase 3 ARTISTS 2 trials developed to evaluate deutetrabenazine compared to placebo for the treatment of tics for chorea treatment failed to meet the primary endpoint of reduction in motor and phonic tics. In the data received this week, the most commonly reported adverse event in the ARTISTS 1 and ARTISTS 2 studies were headache, somnolence, and fatigue. In this population, no new safety signals were identified that were inconsistent with the known safety profile of deutetrabenazine.

Regulatory Insights:
"The American Academy of Neurology (AAN), clinicians should prescribe as much as 100 mg of tetrabenazine per day, between 300 and 400 mg of amantadine per day, or 200 mg of riluzole per day to treat patients with Huntington's disease chorea, according to a new American Academy of Neurology (AAN) guideline published in the July 18 issue of Neurology. Based on the evidence, the guideline recommends that if HD chorea requires treatment, "clinicians may prescribe tetrabenazine (up to 100 mg/day), amantadine (300 to 400 mg/day), or riluzole (200 mg/day) (Level B) for varying degrees of expected benefit."

Influencing Trend:
Continuous Research and Development in Chorea Treatment and Increasing Chorea Treatment for Adults Specially Geriatric Population

Market Growth Drivers:
Rising Prevalence of Genetic Conditions, such as Huntington’s Disease and Increasing Various Neurological Problems like Immune Condition and Metabolic Disorder

Challenges:
Complying with the Regulatory factors Involved with Chorea Treatment

Restraints:
Side Effects Associated with Medications, Surgeries, etc Associated with Chorea Treatment Might be the Hindrance

Opportunities:
Awareness about Neurological Problems will Boost the Chorea Treatment Market and Advancement in the Neurological Department of Healthcare Sector will Lead to Growth in Chorea Treatment

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Chorea Treatment Market
- Analysis about New Entrants in Chorea Treatment Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Chorea Treatment Study Sheds Light on
— The Chorea Treatment Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Chorea Treatment industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Chorea Treatment industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Chorea-Acanthocytosis Treatment
  • Sydenham’s Chorea Treatment
By Application
  • Hospitals
  • Clinics
  • Therapy Center
  • Others
By Treatment
  • Medication
  • - Fluphenazine {Prolixin}
  • - Haloperidol {Haldo}
  • - Olanzapine {Zyprexa}
  • - Quetiapine {Seroque}
  • - Risperidone {Risperdal}
  • Surgery
  • Home Care

By Diagnosis
  • Blood Tests
  • Brain Imaging {Magnetic Resonance Imaging or Computed Tomography}
  • Others

By End User
  • Adults
  • Children
  • Adolescents

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Genetic Conditions, such as Huntington’s Disease
      • 3.2.2. Increasing Various Neurological Problems like Immune Condition and Metabolic Disorder
    • 3.3. Market Challenges
      • 3.3.1. Complying with the Regulatory factors Involved with Chorea Treatment
    • 3.4. Market Trends
      • 3.4.1. Continuous Research and Development in Chorea Treatment
      • 3.4.2. Increasing Chorea Treatment for Adults Specially Geriatric Population
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Chorea Treatment, by Type, Application, Treatment, Diagnosis, End User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Chorea Treatment (Value)
      • 5.2.1. Global Chorea Treatment by: Type (Value)
        • 5.2.1.1. Chorea-Acanthocytosis Treatment
        • 5.2.1.2. Sydenham’s Chorea Treatment
      • 5.2.2. Global Chorea Treatment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Therapy Center
        • 5.2.2.4. Others
      • 5.2.3. Global Chorea Treatment by: Treatment (Value)
        • 5.2.3.1. Medication
        • 5.2.3.2. - Fluphenazine {Prolixin}
        • 5.2.3.3. - Haloperidol {Haldo}
        • 5.2.3.4. - Olanzapine {Zyprexa}
        • 5.2.3.5. - Quetiapine {Seroque}
        • 5.2.3.6. - Risperidone {Risperdal}
        • 5.2.3.7. Surgery
        • 5.2.3.8. Home Care
      • 5.2.4. Global Chorea Treatment by: Diagnosis (Value)
        • 5.2.4.1. Blood Tests
        • 5.2.4.2. Brain Imaging {Magnetic Resonance Imaging or Computed Tomography}
        • 5.2.4.3. Others
      • 5.2.5. Global Chorea Treatment by: End User (Value)
        • 5.2.5.1. Adults
        • 5.2.5.2. Children
        • 5.2.5.3. Adolescents
      • 5.2.6. Global Chorea Treatment Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Chorea Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Medtronic plc (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Boston Scientific Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bausch Health Companies Inc. (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Camber Pharmaceuticals Inc (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. LivaNova, PLC (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. H. Lundbeck A/S (Denmark)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Ipsen (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Amgen Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Aleva Neurotherapeutics SA (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Chorea Treatment Sale, by Type, Application, Treatment, Diagnosis, End User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Chorea Treatment (Value)
      • 7.2.1. Global Chorea Treatment by: Type (Value)
        • 7.2.1.1. Chorea-Acanthocytosis Treatment
        • 7.2.1.2. Sydenham’s Chorea Treatment
      • 7.2.2. Global Chorea Treatment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Therapy Center
        • 7.2.2.4. Others
      • 7.2.3. Global Chorea Treatment by: Treatment (Value)
        • 7.2.3.1. Medication
        • 7.2.3.2. - Fluphenazine {Prolixin}
        • 7.2.3.3. - Haloperidol {Haldo}
        • 7.2.3.4. - Olanzapine {Zyprexa}
        • 7.2.3.5. - Quetiapine {Seroque}
        • 7.2.3.6. - Risperidone {Risperdal}
        • 7.2.3.7. Surgery
        • 7.2.3.8. Home Care
      • 7.2.4. Global Chorea Treatment by: Diagnosis (Value)
        • 7.2.4.1. Blood Tests
        • 7.2.4.2. Brain Imaging {Magnetic Resonance Imaging or Computed Tomography}
        • 7.2.4.3. Others
      • 7.2.5. Global Chorea Treatment by: End User (Value)
        • 7.2.5.1. Adults
        • 7.2.5.2. Children
        • 7.2.5.3. Adolescents
      • 7.2.6. Global Chorea Treatment Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Chorea Treatment: by Type(USD Million)
  • Table 2. Chorea Treatment Chorea-Acanthocytosis Treatment , by Region USD Million (2017-2022)
  • Table 3. Chorea Treatment Sydenham’s Chorea Treatment , by Region USD Million (2017-2022)
  • Table 4. Chorea Treatment: by Application(USD Million)
  • Table 5. Chorea Treatment Hospitals , by Region USD Million (2017-2022)
  • Table 6. Chorea Treatment Clinics , by Region USD Million (2017-2022)
  • Table 7. Chorea Treatment Therapy Center , by Region USD Million (2017-2022)
  • Table 8. Chorea Treatment Others , by Region USD Million (2017-2022)
  • Table 9. Chorea Treatment: by Treatment(USD Million)
  • Table 10. Chorea Treatment Medication , by Region USD Million (2017-2022)
  • Table 11. Chorea Treatment - Fluphenazine {Prolixin} , by Region USD Million (2017-2022)
  • Table 12. Chorea Treatment - Haloperidol {Haldo} , by Region USD Million (2017-2022)
  • Table 13. Chorea Treatment - Olanzapine {Zyprexa} , by Region USD Million (2017-2022)
  • Table 14. Chorea Treatment - Quetiapine {Seroque} , by Region USD Million (2017-2022)
  • Table 15. Chorea Treatment - Risperidone {Risperdal} , by Region USD Million (2017-2022)
  • Table 16. Chorea Treatment Surgery , by Region USD Million (2017-2022)
  • Table 17. Chorea Treatment Home Care , by Region USD Million (2017-2022)
  • Table 18. Chorea Treatment: by Diagnosis(USD Million)
  • Table 19. Chorea Treatment Blood Tests , by Region USD Million (2017-2022)
  • Table 20. Chorea Treatment Brain Imaging {Magnetic Resonance Imaging or Computed Tomography} , by Region USD Million (2017-2022)
  • Table 21. Chorea Treatment Others , by Region USD Million (2017-2022)
  • Table 22. Chorea Treatment: by End User(USD Million)
  • Table 23. Chorea Treatment Adults , by Region USD Million (2017-2022)
  • Table 24. Chorea Treatment Children , by Region USD Million (2017-2022)
  • Table 25. Chorea Treatment Adolescents , by Region USD Million (2017-2022)
  • Table 26. South America Chorea Treatment, by Country USD Million (2017-2022)
  • Table 27. South America Chorea Treatment, by Type USD Million (2017-2022)
  • Table 28. South America Chorea Treatment, by Application USD Million (2017-2022)
  • Table 29. South America Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 30. South America Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 31. South America Chorea Treatment, by End User USD Million (2017-2022)
  • Table 32. Brazil Chorea Treatment, by Type USD Million (2017-2022)
  • Table 33. Brazil Chorea Treatment, by Application USD Million (2017-2022)
  • Table 34. Brazil Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 35. Brazil Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 36. Brazil Chorea Treatment, by End User USD Million (2017-2022)
  • Table 37. Argentina Chorea Treatment, by Type USD Million (2017-2022)
  • Table 38. Argentina Chorea Treatment, by Application USD Million (2017-2022)
  • Table 39. Argentina Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 40. Argentina Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 41. Argentina Chorea Treatment, by End User USD Million (2017-2022)
  • Table 42. Rest of South America Chorea Treatment, by Type USD Million (2017-2022)
  • Table 43. Rest of South America Chorea Treatment, by Application USD Million (2017-2022)
  • Table 44. Rest of South America Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 45. Rest of South America Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 46. Rest of South America Chorea Treatment, by End User USD Million (2017-2022)
  • Table 47. Asia Pacific Chorea Treatment, by Country USD Million (2017-2022)
  • Table 48. Asia Pacific Chorea Treatment, by Type USD Million (2017-2022)
  • Table 49. Asia Pacific Chorea Treatment, by Application USD Million (2017-2022)
  • Table 50. Asia Pacific Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 51. Asia Pacific Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 52. Asia Pacific Chorea Treatment, by End User USD Million (2017-2022)
  • Table 53. China Chorea Treatment, by Type USD Million (2017-2022)
  • Table 54. China Chorea Treatment, by Application USD Million (2017-2022)
  • Table 55. China Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 56. China Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 57. China Chorea Treatment, by End User USD Million (2017-2022)
  • Table 58. Japan Chorea Treatment, by Type USD Million (2017-2022)
  • Table 59. Japan Chorea Treatment, by Application USD Million (2017-2022)
  • Table 60. Japan Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 61. Japan Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 62. Japan Chorea Treatment, by End User USD Million (2017-2022)
  • Table 63. India Chorea Treatment, by Type USD Million (2017-2022)
  • Table 64. India Chorea Treatment, by Application USD Million (2017-2022)
  • Table 65. India Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 66. India Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 67. India Chorea Treatment, by End User USD Million (2017-2022)
  • Table 68. South Korea Chorea Treatment, by Type USD Million (2017-2022)
  • Table 69. South Korea Chorea Treatment, by Application USD Million (2017-2022)
  • Table 70. South Korea Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 71. South Korea Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 72. South Korea Chorea Treatment, by End User USD Million (2017-2022)
  • Table 73. Taiwan Chorea Treatment, by Type USD Million (2017-2022)
  • Table 74. Taiwan Chorea Treatment, by Application USD Million (2017-2022)
  • Table 75. Taiwan Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 76. Taiwan Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 77. Taiwan Chorea Treatment, by End User USD Million (2017-2022)
  • Table 78. Australia Chorea Treatment, by Type USD Million (2017-2022)
  • Table 79. Australia Chorea Treatment, by Application USD Million (2017-2022)
  • Table 80. Australia Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 81. Australia Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 82. Australia Chorea Treatment, by End User USD Million (2017-2022)
  • Table 83. Rest of Asia-Pacific Chorea Treatment, by Type USD Million (2017-2022)
  • Table 84. Rest of Asia-Pacific Chorea Treatment, by Application USD Million (2017-2022)
  • Table 85. Rest of Asia-Pacific Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 86. Rest of Asia-Pacific Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 87. Rest of Asia-Pacific Chorea Treatment, by End User USD Million (2017-2022)
  • Table 88. Europe Chorea Treatment, by Country USD Million (2017-2022)
  • Table 89. Europe Chorea Treatment, by Type USD Million (2017-2022)
  • Table 90. Europe Chorea Treatment, by Application USD Million (2017-2022)
  • Table 91. Europe Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 92. Europe Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 93. Europe Chorea Treatment, by End User USD Million (2017-2022)
  • Table 94. Germany Chorea Treatment, by Type USD Million (2017-2022)
  • Table 95. Germany Chorea Treatment, by Application USD Million (2017-2022)
  • Table 96. Germany Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 97. Germany Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 98. Germany Chorea Treatment, by End User USD Million (2017-2022)
  • Table 99. France Chorea Treatment, by Type USD Million (2017-2022)
  • Table 100. France Chorea Treatment, by Application USD Million (2017-2022)
  • Table 101. France Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 102. France Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 103. France Chorea Treatment, by End User USD Million (2017-2022)
  • Table 104. Italy Chorea Treatment, by Type USD Million (2017-2022)
  • Table 105. Italy Chorea Treatment, by Application USD Million (2017-2022)
  • Table 106. Italy Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 107. Italy Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 108. Italy Chorea Treatment, by End User USD Million (2017-2022)
  • Table 109. United Kingdom Chorea Treatment, by Type USD Million (2017-2022)
  • Table 110. United Kingdom Chorea Treatment, by Application USD Million (2017-2022)
  • Table 111. United Kingdom Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 112. United Kingdom Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 113. United Kingdom Chorea Treatment, by End User USD Million (2017-2022)
  • Table 114. Netherlands Chorea Treatment, by Type USD Million (2017-2022)
  • Table 115. Netherlands Chorea Treatment, by Application USD Million (2017-2022)
  • Table 116. Netherlands Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 117. Netherlands Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 118. Netherlands Chorea Treatment, by End User USD Million (2017-2022)
  • Table 119. Rest of Europe Chorea Treatment, by Type USD Million (2017-2022)
  • Table 120. Rest of Europe Chorea Treatment, by Application USD Million (2017-2022)
  • Table 121. Rest of Europe Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 122. Rest of Europe Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 123. Rest of Europe Chorea Treatment, by End User USD Million (2017-2022)
  • Table 124. MEA Chorea Treatment, by Country USD Million (2017-2022)
  • Table 125. MEA Chorea Treatment, by Type USD Million (2017-2022)
  • Table 126. MEA Chorea Treatment, by Application USD Million (2017-2022)
  • Table 127. MEA Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 128. MEA Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 129. MEA Chorea Treatment, by End User USD Million (2017-2022)
  • Table 130. Middle East Chorea Treatment, by Type USD Million (2017-2022)
  • Table 131. Middle East Chorea Treatment, by Application USD Million (2017-2022)
  • Table 132. Middle East Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 133. Middle East Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 134. Middle East Chorea Treatment, by End User USD Million (2017-2022)
  • Table 135. Africa Chorea Treatment, by Type USD Million (2017-2022)
  • Table 136. Africa Chorea Treatment, by Application USD Million (2017-2022)
  • Table 137. Africa Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 138. Africa Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 139. Africa Chorea Treatment, by End User USD Million (2017-2022)
  • Table 140. North America Chorea Treatment, by Country USD Million (2017-2022)
  • Table 141. North America Chorea Treatment, by Type USD Million (2017-2022)
  • Table 142. North America Chorea Treatment, by Application USD Million (2017-2022)
  • Table 143. North America Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 144. North America Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 145. North America Chorea Treatment, by End User USD Million (2017-2022)
  • Table 146. United States Chorea Treatment, by Type USD Million (2017-2022)
  • Table 147. United States Chorea Treatment, by Application USD Million (2017-2022)
  • Table 148. United States Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 149. United States Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 150. United States Chorea Treatment, by End User USD Million (2017-2022)
  • Table 151. Canada Chorea Treatment, by Type USD Million (2017-2022)
  • Table 152. Canada Chorea Treatment, by Application USD Million (2017-2022)
  • Table 153. Canada Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 154. Canada Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 155. Canada Chorea Treatment, by End User USD Million (2017-2022)
  • Table 156. Mexico Chorea Treatment, by Type USD Million (2017-2022)
  • Table 157. Mexico Chorea Treatment, by Application USD Million (2017-2022)
  • Table 158. Mexico Chorea Treatment, by Treatment USD Million (2017-2022)
  • Table 159. Mexico Chorea Treatment, by Diagnosis USD Million (2017-2022)
  • Table 160. Mexico Chorea Treatment, by End User USD Million (2017-2022)
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Chorea Treatment: by Type(USD Million)
  • Table 172. Chorea Treatment Chorea-Acanthocytosis Treatment , by Region USD Million (2023-2028)
  • Table 173. Chorea Treatment Sydenham’s Chorea Treatment , by Region USD Million (2023-2028)
  • Table 174. Chorea Treatment: by Application(USD Million)
  • Table 175. Chorea Treatment Hospitals , by Region USD Million (2023-2028)
  • Table 176. Chorea Treatment Clinics , by Region USD Million (2023-2028)
  • Table 177. Chorea Treatment Therapy Center , by Region USD Million (2023-2028)
  • Table 178. Chorea Treatment Others , by Region USD Million (2023-2028)
  • Table 179. Chorea Treatment: by Treatment(USD Million)
  • Table 180. Chorea Treatment Medication , by Region USD Million (2023-2028)
  • Table 181. Chorea Treatment - Fluphenazine {Prolixin} , by Region USD Million (2023-2028)
  • Table 182. Chorea Treatment - Haloperidol {Haldo} , by Region USD Million (2023-2028)
  • Table 183. Chorea Treatment - Olanzapine {Zyprexa} , by Region USD Million (2023-2028)
  • Table 184. Chorea Treatment - Quetiapine {Seroque} , by Region USD Million (2023-2028)
  • Table 185. Chorea Treatment - Risperidone {Risperdal} , by Region USD Million (2023-2028)
  • Table 186. Chorea Treatment Surgery , by Region USD Million (2023-2028)
  • Table 187. Chorea Treatment Home Care , by Region USD Million (2023-2028)
  • Table 188. Chorea Treatment: by Diagnosis(USD Million)
  • Table 189. Chorea Treatment Blood Tests , by Region USD Million (2023-2028)
  • Table 190. Chorea Treatment Brain Imaging {Magnetic Resonance Imaging or Computed Tomography} , by Region USD Million (2023-2028)
  • Table 191. Chorea Treatment Others , by Region USD Million (2023-2028)
  • Table 192. Chorea Treatment: by End User(USD Million)
  • Table 193. Chorea Treatment Adults , by Region USD Million (2023-2028)
  • Table 194. Chorea Treatment Children , by Region USD Million (2023-2028)
  • Table 195. Chorea Treatment Adolescents , by Region USD Million (2023-2028)
  • Table 196. South America Chorea Treatment, by Country USD Million (2023-2028)
  • Table 197. South America Chorea Treatment, by Type USD Million (2023-2028)
  • Table 198. South America Chorea Treatment, by Application USD Million (2023-2028)
  • Table 199. South America Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 200. South America Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 201. South America Chorea Treatment, by End User USD Million (2023-2028)
  • Table 202. Brazil Chorea Treatment, by Type USD Million (2023-2028)
  • Table 203. Brazil Chorea Treatment, by Application USD Million (2023-2028)
  • Table 204. Brazil Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 205. Brazil Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 206. Brazil Chorea Treatment, by End User USD Million (2023-2028)
  • Table 207. Argentina Chorea Treatment, by Type USD Million (2023-2028)
  • Table 208. Argentina Chorea Treatment, by Application USD Million (2023-2028)
  • Table 209. Argentina Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 210. Argentina Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 211. Argentina Chorea Treatment, by End User USD Million (2023-2028)
  • Table 212. Rest of South America Chorea Treatment, by Type USD Million (2023-2028)
  • Table 213. Rest of South America Chorea Treatment, by Application USD Million (2023-2028)
  • Table 214. Rest of South America Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 215. Rest of South America Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 216. Rest of South America Chorea Treatment, by End User USD Million (2023-2028)
  • Table 217. Asia Pacific Chorea Treatment, by Country USD Million (2023-2028)
  • Table 218. Asia Pacific Chorea Treatment, by Type USD Million (2023-2028)
  • Table 219. Asia Pacific Chorea Treatment, by Application USD Million (2023-2028)
  • Table 220. Asia Pacific Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 221. Asia Pacific Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 222. Asia Pacific Chorea Treatment, by End User USD Million (2023-2028)
  • Table 223. China Chorea Treatment, by Type USD Million (2023-2028)
  • Table 224. China Chorea Treatment, by Application USD Million (2023-2028)
  • Table 225. China Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 226. China Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 227. China Chorea Treatment, by End User USD Million (2023-2028)
  • Table 228. Japan Chorea Treatment, by Type USD Million (2023-2028)
  • Table 229. Japan Chorea Treatment, by Application USD Million (2023-2028)
  • Table 230. Japan Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 231. Japan Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 232. Japan Chorea Treatment, by End User USD Million (2023-2028)
  • Table 233. India Chorea Treatment, by Type USD Million (2023-2028)
  • Table 234. India Chorea Treatment, by Application USD Million (2023-2028)
  • Table 235. India Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 236. India Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 237. India Chorea Treatment, by End User USD Million (2023-2028)
  • Table 238. South Korea Chorea Treatment, by Type USD Million (2023-2028)
  • Table 239. South Korea Chorea Treatment, by Application USD Million (2023-2028)
  • Table 240. South Korea Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 241. South Korea Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 242. South Korea Chorea Treatment, by End User USD Million (2023-2028)
  • Table 243. Taiwan Chorea Treatment, by Type USD Million (2023-2028)
  • Table 244. Taiwan Chorea Treatment, by Application USD Million (2023-2028)
  • Table 245. Taiwan Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 246. Taiwan Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 247. Taiwan Chorea Treatment, by End User USD Million (2023-2028)
  • Table 248. Australia Chorea Treatment, by Type USD Million (2023-2028)
  • Table 249. Australia Chorea Treatment, by Application USD Million (2023-2028)
  • Table 250. Australia Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 251. Australia Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 252. Australia Chorea Treatment, by End User USD Million (2023-2028)
  • Table 253. Rest of Asia-Pacific Chorea Treatment, by Type USD Million (2023-2028)
  • Table 254. Rest of Asia-Pacific Chorea Treatment, by Application USD Million (2023-2028)
  • Table 255. Rest of Asia-Pacific Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 256. Rest of Asia-Pacific Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 257. Rest of Asia-Pacific Chorea Treatment, by End User USD Million (2023-2028)
  • Table 258. Europe Chorea Treatment, by Country USD Million (2023-2028)
  • Table 259. Europe Chorea Treatment, by Type USD Million (2023-2028)
  • Table 260. Europe Chorea Treatment, by Application USD Million (2023-2028)
  • Table 261. Europe Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 262. Europe Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 263. Europe Chorea Treatment, by End User USD Million (2023-2028)
  • Table 264. Germany Chorea Treatment, by Type USD Million (2023-2028)
  • Table 265. Germany Chorea Treatment, by Application USD Million (2023-2028)
  • Table 266. Germany Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 267. Germany Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 268. Germany Chorea Treatment, by End User USD Million (2023-2028)
  • Table 269. France Chorea Treatment, by Type USD Million (2023-2028)
  • Table 270. France Chorea Treatment, by Application USD Million (2023-2028)
  • Table 271. France Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 272. France Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 273. France Chorea Treatment, by End User USD Million (2023-2028)
  • Table 274. Italy Chorea Treatment, by Type USD Million (2023-2028)
  • Table 275. Italy Chorea Treatment, by Application USD Million (2023-2028)
  • Table 276. Italy Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 277. Italy Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 278. Italy Chorea Treatment, by End User USD Million (2023-2028)
  • Table 279. United Kingdom Chorea Treatment, by Type USD Million (2023-2028)
  • Table 280. United Kingdom Chorea Treatment, by Application USD Million (2023-2028)
  • Table 281. United Kingdom Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 282. United Kingdom Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 283. United Kingdom Chorea Treatment, by End User USD Million (2023-2028)
  • Table 284. Netherlands Chorea Treatment, by Type USD Million (2023-2028)
  • Table 285. Netherlands Chorea Treatment, by Application USD Million (2023-2028)
  • Table 286. Netherlands Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 287. Netherlands Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 288. Netherlands Chorea Treatment, by End User USD Million (2023-2028)
  • Table 289. Rest of Europe Chorea Treatment, by Type USD Million (2023-2028)
  • Table 290. Rest of Europe Chorea Treatment, by Application USD Million (2023-2028)
  • Table 291. Rest of Europe Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 292. Rest of Europe Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 293. Rest of Europe Chorea Treatment, by End User USD Million (2023-2028)
  • Table 294. MEA Chorea Treatment, by Country USD Million (2023-2028)
  • Table 295. MEA Chorea Treatment, by Type USD Million (2023-2028)
  • Table 296. MEA Chorea Treatment, by Application USD Million (2023-2028)
  • Table 297. MEA Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 298. MEA Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 299. MEA Chorea Treatment, by End User USD Million (2023-2028)
  • Table 300. Middle East Chorea Treatment, by Type USD Million (2023-2028)
  • Table 301. Middle East Chorea Treatment, by Application USD Million (2023-2028)
  • Table 302. Middle East Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 303. Middle East Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 304. Middle East Chorea Treatment, by End User USD Million (2023-2028)
  • Table 305. Africa Chorea Treatment, by Type USD Million (2023-2028)
  • Table 306. Africa Chorea Treatment, by Application USD Million (2023-2028)
  • Table 307. Africa Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 308. Africa Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 309. Africa Chorea Treatment, by End User USD Million (2023-2028)
  • Table 310. North America Chorea Treatment, by Country USD Million (2023-2028)
  • Table 311. North America Chorea Treatment, by Type USD Million (2023-2028)
  • Table 312. North America Chorea Treatment, by Application USD Million (2023-2028)
  • Table 313. North America Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 314. North America Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 315. North America Chorea Treatment, by End User USD Million (2023-2028)
  • Table 316. United States Chorea Treatment, by Type USD Million (2023-2028)
  • Table 317. United States Chorea Treatment, by Application USD Million (2023-2028)
  • Table 318. United States Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 319. United States Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 320. United States Chorea Treatment, by End User USD Million (2023-2028)
  • Table 321. Canada Chorea Treatment, by Type USD Million (2023-2028)
  • Table 322. Canada Chorea Treatment, by Application USD Million (2023-2028)
  • Table 323. Canada Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 324. Canada Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 325. Canada Chorea Treatment, by End User USD Million (2023-2028)
  • Table 326. Mexico Chorea Treatment, by Type USD Million (2023-2028)
  • Table 327. Mexico Chorea Treatment, by Application USD Million (2023-2028)
  • Table 328. Mexico Chorea Treatment, by Treatment USD Million (2023-2028)
  • Table 329. Mexico Chorea Treatment, by Diagnosis USD Million (2023-2028)
  • Table 330. Mexico Chorea Treatment, by End User USD Million (2023-2028)
  • Table 331. Research Programs/Design for This Report
  • Table 332. Key Data Information from Secondary Sources
  • Table 333. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Chorea Treatment: by Type USD Million (2017-2022)
  • Figure 5. Global Chorea Treatment: by Application USD Million (2017-2022)
  • Figure 6. Global Chorea Treatment: by Treatment USD Million (2017-2022)
  • Figure 7. Global Chorea Treatment: by Diagnosis USD Million (2017-2022)
  • Figure 8. Global Chorea Treatment: by End User USD Million (2017-2022)
  • Figure 9. South America Chorea Treatment Share (%), by Country
  • Figure 10. Asia Pacific Chorea Treatment Share (%), by Country
  • Figure 11. Europe Chorea Treatment Share (%), by Country
  • Figure 12. MEA Chorea Treatment Share (%), by Country
  • Figure 13. North America Chorea Treatment Share (%), by Country
  • Figure 14. Global Chorea Treatment share by Players 2022 (%)
  • Figure 15. Global Chorea Treatment share by Players (Top 3) 2022(%)
  • Figure 16. Global Chorea Treatment share by Players (Top 5) 2022(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 19. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2022
  • Figure 20. Medtronic plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 21. Medtronic plc (Ireland) Revenue: by Geography 2022
  • Figure 22. Boston Scientific Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 23. Boston Scientific Corporation (United States) Revenue: by Geography 2022
  • Figure 24. Bausch Health Companies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 25. Bausch Health Companies Inc. (Canada) Revenue: by Geography 2022
  • Figure 26. Camber Pharmaceuticals Inc (United States) Revenue, Net Income and Gross profit
  • Figure 27. Camber Pharmaceuticals Inc (United States) Revenue: by Geography 2022
  • Figure 28. LivaNova, PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. LivaNova, PLC (United Kingdom) Revenue: by Geography 2022
  • Figure 30. H. Lundbeck A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 31. H. Lundbeck A/S (Denmark) Revenue: by Geography 2022
  • Figure 32. Ipsen (France) Revenue, Net Income and Gross profit
  • Figure 33. Ipsen (France) Revenue: by Geography 2022
  • Figure 34. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Amgen Inc. (United States) Revenue: by Geography 2022
  • Figure 36. Aleva Neurotherapeutics SA (Switzerland) Revenue, Net Income and Gross profit
  • Figure 37. Aleva Neurotherapeutics SA (Switzerland) Revenue: by Geography 2022
  • Figure 38. Global Chorea Treatment: by Type USD Million (2023-2028)
  • Figure 39. Global Chorea Treatment: by Application USD Million (2023-2028)
  • Figure 40. Global Chorea Treatment: by Treatment USD Million (2023-2028)
  • Figure 41. Global Chorea Treatment: by Diagnosis USD Million (2023-2028)
  • Figure 42. Global Chorea Treatment: by End User USD Million (2023-2028)
  • Figure 43. South America Chorea Treatment Share (%), by Country
  • Figure 44. Asia Pacific Chorea Treatment Share (%), by Country
  • Figure 45. Europe Chorea Treatment Share (%), by Country
  • Figure 46. MEA Chorea Treatment Share (%), by Country
  • Figure 47. North America Chorea Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Medtronic plc (Ireland)
  • Boston Scientific Corporation (United States)
  • Bausch Health Companies Inc. (Canada)
  • Camber Pharmaceuticals Inc (United States)
  • LivaNova, PLC (United Kingdom)
  • H. Lundbeck A/S (Denmark)
  • Ipsen (France)
  • Amgen Inc. (United States)
  • Aleva Neurotherapeutics SA (Switzerland)
Additional players considered in the study are as follows:
Vertex Pharmaceuticals, Inc. (United States) , SOM Biotech (Spain)
Select User Access Type

Key Highlights of Report


May 2023 227 Pages 65 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Chorea Treatment Market Quantitative research analysis
Global Chorea Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Chorea Treatment market are Teva Pharmaceutical Industries Ltd. (Israel), Medtronic plc (Ireland), Boston Scientific Corporation (United States), Bausch Health Companies Inc. (Canada), Camber Pharmaceuticals Inc (United States), LivaNova, PLC (United Kingdom), H. Lundbeck A/S (Denmark), Ipsen (France), Amgen Inc. (United States) and Aleva Neurotherapeutics SA (Switzerland), to name a few.
is dominating the Chorea Treatment Market.
"Complying with the Regulatory factors Involved with Chorea Treatment" is seen as one of the major challenges by many Industry Players of Chorea Treatment Market
The Chorea Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Chorea Treatment market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Chorea Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Nucleic Acid Testing Comprehensive Study by Type (Nucleic Acid Test Kits, Consumables), Nucleic Acid Test Kits (Ligase Chain Reaction (LCR), Transcription–mediated Amplification (TMA), Polymerase Cha...
$ 3750
Neuroscience Comprehensive Study by Type (Whole Brain Imaging, Neuro-microscopy, Electrophysiology, Neuro-functional analysis, Neuro-proteomic analysis, Neuro-cellular manipulation, Neuro-biochemical...
$ 3750
Healthcare Gamification Comprehensive Study by Type (Enterprise-based solutions, Consumer-based solutions), Application (Fitness management, Medical Training, Medication Management, Physical Therapy,...
$ 3500
Early Toxicity Testing Comprehensive Study by End Users (Pharmaceuticals Industry, Diagnostics Industry, Food Industry, Chemicals Industry, Cosmetics Industry, Others), Toxicity End-points (Dermal To...
$ 3750
Milk Allergy Clinical Trial Comprehensive Study by Type (Skin Prick Tests, Blood Allergen-Specific IgE Tests, Oral Food Challenge, Food Elimination Diet, Others), Application (Immediate Treatment, Ma...
$ 3750
Primary Biliary Cholangitis Treatment Comprehensive Study by Drug Type (Ursodeoxycholic acid (UDCA), Obeticholic acid (Ocaliva), Corticosteroids, Methotrexate, Others), Blood Test (Blood test, Liver...
$ 3350